Back to news

Haemonetics Announces CE Mark Certification for the VASCADE MVP® XL Venous Vascular Closure System

PR Newswire•18/11/2026•06:15 ET
1

Key Highlights

  • ➤Haemonetics (HAE) receives CE Mark certification for VASCADE MVP XL under EU-MDR
  • ➤First European VASCADE MVP XL procedures completed in Germany, Italy and the UK
  • ➤VASCADE MVP XL targets 10–12F venous access procedures, including cryoablation and PFA
  • ➤VASCADE MVP XL uses 58% more collagen and a 9% larger disc than MVP

Expert Statements

Ken Crowley, Vice President and General Manager, Interventional Technologies at Haemonetics

“VASCADE MVP XL has driven the growth of our Interventional Technologies business in the United States, delivering physicians key benefits in larger-bore venous closure supported by clinical evidence. With CE Mark certification and the first cases completed in Europe, we look forward to significantly expanding our impact and commercial momentum in electrophysiology and interventional cardiology as we help raise standards of care for a larger population of patients in new markets around the world”

Christian H. Heeger, Director Department of Rhythmology at Asklepios Clinic Altona in Hamburg, Germany

“The VASCADE MVP system has become an important part of our approach to post-procedure care, helping us shorten time to ambulation and facilitate earlier discharge for appropriate patients. With the VASCADE MVP XL system, we can now apply the same closure technology more confidently in procedures requiring larger venous access within the approved indication.”

Haemonetics Announces CE Mark Certification for the VASCADE MVP® XL Venous Vascular Closure System PR Newswire

First Commercial European Procedures Completed in Germany, Italy and the UK

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in